文献速递泌尿男性生殖肿瘤

CALGB 90203研究:高危局限前列腺癌新辅助化激素治疗联合根治术

Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
PubMed 文献 · J Clin Oncol · 2020-07-24

研究纳入788例临床局限高危前列腺癌男性,随机接受单纯根治性前列腺切除术或新辅助化激素治疗(雄激素剥夺联合多西他赛75 mg/m2每3周6周期)后手术。主要终点3年生化无进展生存(BPFS)未达统计学差异(0.89 vs 0.84,95%CI -0.01至0.11,P=0.11),但新辅助治疗改善总BPFS(HR 0.69)、无转移生存(HR 0.70)和总生存(HR 0.61)。结论不支持常规使用新辅助化激素治疗。

要点

  • 主要终点3年BPFS未达统计学差异(P=0.11)。
  • 新辅助化激素治疗改善总BPFS、MFS和OS等次要终点。
  • 化疗期间3级和4级不良事件发生率分别为26%和19%。

核心结论

  • 主要研究终点3年BPFS未达到,新辅助化激素治疗联合根治术不应常规用于临床局限高危前列腺癌患者。

研究设计与样本

  • 随机对照研究,纳入788例临床局限高危前列腺癌男性,随机分配至单纯根治性前列腺切除术或新辅助化激素治疗(雄激素剥夺联合多西他赛75 mg/m2体表面积每3周6周期)后手术。
  • 主要终点为3年BPFS,生化失败定义为血清前列腺特异性抗原水平>0.2 ng/mL且间隔至少3个月的连续两次升高。
  • 中位随访时间6.1年。

主要发现

  • 新辅助化激素治疗联合手术与单纯手术的3年BPFS分别为0.89和0.84,差异95%CI为-0.01至0.11,P=0.11。
  • 新辅助化激素治疗相比单纯手术改善总BPFS(HR 0.69,95%CI 0.48至0.99)。
  • 新辅助化激素治疗相比单纯手术改善无转移生存(HR 0.70,95%CI 0.51至0.95)。
  • 新辅助化激素治疗相比单纯手术改善总生存(HR 0.61,95%CI 0.40至0.94)。
  • 化疗期间3级和4级不良事件总体发生率分别为26%和19%。

临床怎么用

  • 临床局限高危前列腺癌患者不应常规接受新辅助化激素治疗联合根治性前列腺切除术。
  • 新辅助化激素治疗虽改善部分次要终点,但需权衡化疗相关毒性(3级26%、4级19%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radical prostatectomy (RP) alone is often inadequate in curing men with clinically localized, high-risk prostate cancer (PC). We hypothesized that chemohormonal therapy (CHT) with androgen-deprivation therapy plus docetaxel before RP would improve biochemical progression-free survival (BPFS) over RP alone. PATIENTS AND METHODS: Men with clinically localized, high-risk PC were assigned to RP alone or neoadjuvant CHT with androgen deprivation plus docetaxel (75 mg/m2 body surface area every 3 weeks for 6 cycles) and RP. The primary end point was 3-year BPFS. Biochemical failure was defined as a serum prostate-specific antigen level > 0.2 ng/mL that increased on 2 consecutive occasions that were at least 3 months apart. Secondary end points included 5-year BPFS, overall BPFS, local recurrence, metastasis-free survival (MFS), PC-specific mortality, and overall survival (OS). RESULTS: In total, 788 men were randomly assigned. Median follow-up time was 6.1 years. The overall rates of grade 3 and 4 adverse events during chemotherapy were 26% and 19%, respectively. No difference was seen in 3-year BPFS between neoadjuvant CHT plus RP and RP alone (0.89 v 0.84, respectively; 95% CI for the difference, -0.01 to 0.11; P = .11). Neoadjuvant CHT was associated with improved overall BPFS (hazard ratio [HR], 0.69; 95% CI, 0.48 to 0.99), improved MFS (HR, 0.70; 95% CI, 0.51 to 0.95), and improved OS (HR, 0.61; 95% CI, 0.40 to 0.94) compared with RP alone. CONCLUSION: The primary study end point, 3-year BPFS, was not met. Although some improvement was seen in secondary end points, any potential benefit must be weighed against toxicity. Our data do not support the routine use of neoadjuvant CHT and RP in patients with clinically localized, high-risk PC at this time.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Eastham JA, Heller G, Halabi S, et al. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. J Clin Oncol. 2020. PMID: 32706639. doi:10.1200/JCO.20.00315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。